Warfarin dose and INR related to genotypes of CYP2C9 and VKORC1 in patients with myocardial infarction

Warfarin dose and INR related to genotypes of CYP2C9 and VKORC1 in patients with myocardial infarction

<p>Abstract</p> <p>Background</p> <p>Warfarin treatment has a narrow therapeutic range, requiring meticulous monitoring and dosage titration. Individual dosage requirement has recently partly been explained by genetic variation of the warfarin metabolizing enzyme CYP2C9...

Full description

Bibliographic Details
Main Authors:	Seljeflot Ingebjørg, Kierulf Peter, Johansen Per, Sjaatil Stine T, Narum Sigrid, Kringen Marianne K, Sharikabad Mohammad N, Haug Kari, Arnesen Harald, Brørs Odd
Format:	Article
Language:	English
Published:	BMC 2008-06-01
Series:	Thrombosis Journal
Online Access:	http://www.thrombosisjournal.com/content/6/1/7

Similar Items

Lack of correlation between INR and warfarin dose: a role of pharmacogenotyping of CYP2C9*3 and VKORC1 for anticoagulation
by: Salleh, Mohd Zaki, et al.
Published: (2009)

Polymorphisms of VKORC1 and CYP2C9 are associated with warfarin sensitivity in Chinese population
by: Jia LQ, et al.
Published: (2017-03-01)

VKORC1 Haplotypes in patients treated with warfarin
by: Beshna, E, et al.
Published: (2010)

Pharmacogenetics of VKORC1 in warfarin resistant patients.
by: Ong, Jacqueline Kai Mei.
Published: (2010)

Contribution of VKORC1 and CYP2C9 polymorphisms in the interethnic variability of warfarin dose in Malaysian populations
by: Gan, G.G., et al.
Published: (2011)

Methylation of CYP1A1 and VKORC1 promoter associated with stable dosage of warfarin in Chinese patients
by: Shiwei He, et al.
Published: (2021-06-01)

Identification of CYP2C9 and VKORC1 polymorphisms in Iranian patients who are under warfarin therapy
by: Behzad Poopak, et al.
Published: (2016-02-01)

VKORC1 and CYP2C9 Genotype Variations in Relation to Warfarin Dosing in Korean Stroke Patients
by: Sea Mi Park, et al.
Published: (2013-05-01)

PK/PD of warfarin associated with genetic polymorphisms of VKORC1 and CYP2C9 in indonesian patients
by: Taofik Rusdiana, et al.
Published: (2012-01-01)

Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis.
by: Andrea L Jorgensen, et al.
Published: (2012-01-01)

Evaluation of the VKORC 1 and CYP2C9 Gene Polymorphisms and Their Effects on the Emergency Complications in the Patients Using Warfarin
by: Oğuz Yardım, et al.
Published: (2017-06-01)

Determination of Pleiotropic Effect of Warfarin in VKORC1 and CYP2C9 Genotypes in Patients With Heart Valve Replacement
by: Huma Shafique, et al.
Published: (2022-06-01)

A child with Kawasaki disease and genetic warfarin sensitivity from CYP2C9 and VKORC1 gene variants
by: Myeongseob Lee, et al.
Published: (2020-12-01)

The Effect of CYP2C9 and VKORC1 Genetic Polymorphism on Warfarin Dose Requirements in a Sample of Iraqi Patients
by: Maha Ali Saleh, et al.
Published: (2021-03-01)

VKORC1 and Novel CYP2C9 Variation Predict Warfarin Response in Alaska Native and American Indian People
by: Lindsay M. Henderson, et al.
Published: (2019-05-01)

To study role of clinical variables and VKORC1 polymorphism in determination of stability of INR in neurological patients on acenocoumarol
by: Ashish Kant Dubey, et al.
Published: (2017-10-01)

A cardiovascular phenotype in warfarin-resistant Vkorc1 mutant rats☆
by: Michael H. Kohn, et al.
Published: (2008-11-01)

Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin
by: Teh, L. K., et al.
Published: (2011)

A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose.
by: Fumihiko Takeuchi, et al.
Published: (2009-03-01)

The role of interleukin-18 in the metabolic syndrome
by: Seljeflot Ingebjørg, et al.
Published: (2010-03-01)

Comparisons of Methods and Outcomes of Warfarin Guideline-based Management in Patients on Warfarin Therapy whose International Normalized Ratio (INR) is Higher than Target INR at Vachiraphuket Hospital
by: Tulaya Potaros, et al.
Published: (2018-08-01)

Association between genetic polymorphisms of CYP2C9 and VKORC1 and safety and efficacy of warfarin: Results of a 5 years audit
by: Mansij Biswas, et al.
Published: (2018-12-01)

The impact of aripiprazole on INR in a psychotic patient during warfarin therapy
by: Taha Can Tuman
Published: (2018-10-01)

Effect of olanzapine treatment on INR of a patient receiving warfarin therapy
by: Derya Arslan, et al.
Published: (2016-06-01)

Effect of olanzapine treatment on INR of a patient receiving warfarin therapy
by: Derya Arslan, et al.
Published: (2016-06-01)

Polymorphisms of CYP2C9*2, CYP2C9*3 and VKORC1 genes related to time in therapeutic range in patients with atrial fibrillation using warfarin
by: Silveira MMBM, et al.
Published: (2019-08-01)

The effect of CYP2C9*2, CYP2C9*3, and VKORC1-1639 G>A polymorphism in patients under warfarin therapy in city of Kermanshah
by: Zohreh Hosseinkhani, et al.
Published: (2018-01-01)

Very Long Chain Marine <i>n</i>-3 Polyunsaturated Fatty Acids in Atherothrombotic Heart Disease. A Brief Review, with a Focus on Metabolic Effects
by: Harald Arnesen, et al.
Published: (2020-09-01)

Frequency of two VKORC1 gene variants and its correlation with warfarin maintenance dose
by: esmat khaleqsefat, et al.
Published: (2018-12-01)

Genetic and Non-Genetic Factors Impact on INR Normalization in Preprocedural Warfarin Management
by: Eljilany I, et al.
Published: (2021-08-01)

Hyper-responsiveness to warfarin in a young patient with the VKORC1 -1639GA/CYP2C9*1*46 genotype: a case report
by: Weam Aldiban, et al.
Published: (2022-10-01)

A brief review on resistance to P2Y12 receptor antagonism in coronary artery disease
by: Ellen M. K. Warlo, et al.
Published: (2019-05-01)

VKORC1 gene polymorphism (-1639G>A) in warfarin therapy patients of Pakistani population
by: Muhammad Bilal Ghafoor, et al.
Published: (2022-02-01)

Impact of VKORC1, CYP4F2 and NQO1 gene variants on warfarin dose requirement in Han Chinese patients with catheter ablation for atrial fibrillation
by: Jiao Li, et al.
Published: (2018-05-01)

Polymorphism of the CYP2C9 and VKORC1 genes: a comment
by: Rujittika Mungmunpuntipantip, et al.
Published: (2021-09-01)

Frequencies of VKORC1-1639G>A and rs397509427 in Patients on Warfarin and Healthy Syrian Subjects
by: Yara Altawil, et al.
Published: (2023-01-01)

VKORC1 pharmacogenetics and pharmacoproteomics in patients on warfarin anticoagulant therapy: transthyretin precursor as a potential biomarker.
by: Ramasamy Saminathan, et al.
Published: (2010-12-01)

Efficacy and Safety of Warfarin Therapy: Comparison Between Specialized INR Clinic and General Medical Clinic
by: Osman Elsayed Osman, et al.
Published: (2022-12-01)

Does prophylactic antibiotic administration for tooth extraction affect PT-INR in patients taking warfarin?
by: Eiji Iwata, et al.
Published: (2020-11-01)

The co-existence of the IL-18+183 A/G and MMP-9 -1562 C/T polymorphisms is associated with clinical events in coronary artery disease patients.
by: Trine B Opstad, et al.
Published: (2013-01-01)